AI
CRDL

AdvisorShares Investments’s Cardiol Therapeutics CRDL Stock Holding History

AdvisorShares Investments’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-597,977
Closed -$570K – 284
2025
Q4 		$570K Buy
597,977
+40,589
+7% +$42.5K 0.1% 104
2025
Q3 		$596K Sell
557,388
-300,000
-35% -$364K 0.1% 106
2025
Q2 		$1.17M Sell
857,388
-125,100
-13% -$146K 0.21% 58
2025
Q1 		$911K Buy
982,488
+100,000
+11% +$123K 0.18% 62
2024
Q4 		$1.13M Sell
882,488
-288,381
-25% -$486K 0.22% 47
2024
Q3 		$2.32M Sell
1,170,869
-296,103
-20% -$614K 0.44% 37
2024
Q2 		$2.93M Buy
1,466,972
+164,994
+13% +$350K 0.51% 38
2024
Q1 		$2.36M Buy
1,301,978
+112,000
+9% +$151K 0.4% 37
2023
Q4 		$1,000K Sell
1,189,978
-15,810
-1% -$13.4K 0.23% 46
2023
Q3 		$1.11M Sell
1,205,788
-13,950
-1% -$13.3K 0.3% 39
2023
Q2 		$1.09M Buy
1,219,738
+40,000
+3% +$26.4K 0.31% 37
2023
Q1 		$575K Buy
1,179,738
+78,948
+7% +$46.7K 0.18% 48
2022
Q4 		$733K Buy
+1,100,790
New +$671K 0.21% 84

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AdvisorShares Investments's CRDL Position: Q1 2026 in Review

AdvisorShares Investments sold out of Cardiol Therapeutics (CRDL) in Q1 2026, closing a stake of 597,977 shares — an estimated $570K sold.

AdvisorShares Investments first reported a position in CRDL in Q4 2022 and held it in 13 quarters. The position peaked at $2.93M in Q2 2024. 47 funds tracked by Wall St. Rank hold CRDL as of Q1 2026.

  • AdvisorShares Investments reported no remaining Cardiol Therapeutics position as of Q1 2026 after selling out during the quarter.
  • AdvisorShares Investments sold 597,977 Cardiol Therapeutics shares in Q1 2026, an estimated $570K.
  • AdvisorShares Investments first reported a position in Cardiol Therapeutics in Q4 2022 and held it in 13 quarters.
  • AdvisorShares Investments's Cardiol Therapeutics position peaked at $2.93M in Q2 2024.
  • 47 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q1 2026.

Based on AdvisorShares Investments's 13F filing for Q1 2026, filed 28 Apr 2026.